
Pharma urges leaders to reverse Europe’s declining competitiveness
An open letter from the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi has urged European governments to create conditions that attract investment in next-generation medicines. They argue that Europe is losing ground to global competition, with over $600 billion in pharmaceutical investment announced… Read More














